Osteonecrosis is a pathological condition characterized by disturbances in microcirculation, osteolysis, and subsequent bone collapse, leading to significant pain and motor impairments that severely affect the quality of life of affected individuals. The primary therapeutic goal in osteonecrosis is the restoration of bone integrity, typically through bone grafting or the use of tissue-engineered constructs. Despite the critical importance of these approaches, a systematic and comprehensive review of the field remains lacking. This study aims to provide a thorough bibliometric analysis of the current state and key research trends in bone regeneration for osteonecrosis.
Methods:
A systematic search of the Web of Science Core Collection, Scopus, and OpenAlex was conducted for studies published between 2001 and 2024, yielding a total of 1,548 publications related to “osteonecrosis and bone regeneration.” Bibliometric tools, including VOSviewer, CiteSpace, and the R package “bibliometrix,” were utilized for data analysis.
Results:
The analysis revealed a notable increase in the number of publications over the years, with China leading the global output at 38.6%, followed by the United States (16.4%) and Japan (5.2%). Shanghai Jiao Tong University and researcher Ling Qin were identified as key contributors to the field. The journal International Orthopaedics emerged as a highly active outlet, while Bone was recognized for its significant impact. Research efforts have primarily focused on bone grafts, tissue engineering, and mesenchymal stem cells, with emerging interest in the integration of exosomes, apoptosis, oxidative stress, and immunomodulation in regenerative therapy.
Conclusion:
This bibliometric review highlights the leading contributors to the field of osteonecrosis research and identifies key trends in bone regeneration strategies. The findings underscore the progressive advancements in the field and suggest promising avenues for future research.
Impact Statement
This study presents the first comprehensive bibliometric analysis of global research trends in bone regeneration for osteonecrosis over the past 24 years. By leveraging advanced computational tools—VOSviewer, CiteSpace, and bibliometrix—we systematically map the evolution of the field, identifying leading contributors, seminal publications, and emerging thematic clusters. Our analysis highlights a shifting focus toward stem cell-based therapies, oxidative stress, exosomes, and immunomodulation, with China, the United States, Germany, and Japan as major contributors. The study uncovers rapidly growing interest in apoptosis, extracellular vesicles, and glucocorticoid-induced osteonecrosis, providing a data-driven foundation for future research. This work not only synthesizes a fragmented body of literature but also identifies underexplored areas, offering valuable insights for guiding innovative therapeutic strategies and clinical translations in tissue engineering and regenerative medicine.
ChangC, GreenspanA, GershwinME. The pathogenesis, diagnosis and clinical manifestations of steroid-induced osteonecrosis. J Autoimmun, 2020; 110:102460; doi: 10.1016/j.jaut.2020.102460
3.
QuanH, RenC, HeY, et al.Application of biomaterials in treating early osteonecrosis of the femoral head: Research progress and future perspectives. Acta Biomater, 2023; 164:15–73; doi: 10.1016/j.actbio.2023.04.005
4.
YaromN, ShapiroCL, PetersonDE, et al.Medication-Related osteonecrosis of the Jaw: MASCC/ISOO/ASCO clinical practice guideline. J Clin Oncol, 2019; 37(25):2270–2290; doi: 10.1200/jco.19.01186
5.
BergmanJ, NordströmA, NordströmP. Epidemiology of osteonecrosis among older adults in Sweden. Osteoporos Int, 2019; 30(5):965–973; doi: 10.1007/s00198-018-04826-2
6.
CooperC, SteinbuchM, StevensonR, et al.The epidemiology of osteonecrosis: Findings from the GPRD and THIN databases in the UK. Osteoporos Int, 2010; 21(4):569–577; doi: 10.1007/s00198-009-1003-1
7.
MassariL, FiniM, CadossiR, et al.Biophysical stimulation with pulsed electromagnetic fields in osteonecrosis of the femoral head. J Bone Joint Surg Am, 2006; 88(Suppl 3):56–60; doi: 10.2106/jbjs.F.00536
8.
MoghamisI, AlhammoudAA, KokashO, et al.The outcome of hyperbaric oxygen therapy versus core decompression in the non-traumatic avascular necrosis of the femoral head: Retrospective Cohort Study. Ann Med Surg (Lond), 2021; 62:450–454; doi: 10.1016/j.amsu.2021.01.084
9.
XieK, MaoY, QuX, et al.High-energy extracorporeal shock wave therapy for nontraumatic osteonecrosis of the femoral head. J Orthop Surg Res, 2018; 13(1):25; doi: 10.1186/s13018-017-0705-x
10.
EtemadifarM, KooskzariM, KhalilollahN, et al.The results of core decompression treatment in patients with avascular necrosis of femoral head in patients at Isfahan City educational hospitals in 2010-2011. Adv Biomed Res, 2014; 3:93; doi: 10.4103/2277-9175.129363
11.
LauHW, WongKC, HoK, et al.Long-term outcome of vascularized iliac bone grafting for osteonecrosis of femoral head: A retrospective study with 17-year follow-up. J Orthop Surg (Hong Kong), 2021; 29(1):2309499021996842; doi: 10.1177/2309499021996842
12.
WangBL, SunW, ShiZC, et al.Treatment of nontraumatic osteonecrosis of the femoral head with the implantation of core decompression and concentrated autologous bone marrow containing mononuclear cells. Arch Orthop Trauma Surg, 2010; 130(7):859–865; doi: 10.1007/s00402-009-0939-0
13.
ScullySP, AaronRK, UrbaniakJR. Survival analysis of hips treated with core decompression or vascularized fibular grafting because of avascular necrosis. J Bone Joint Surg Am, 1998; 80(9):1270–1275; doi: 10.2106/00004623-199809000-00004
14.
XianH, LuoD, WangL, et al.Platelet-Rich plasma-incorporated autologous granular bone grafts improve outcomes of post-traumatic osteonecrosis of the femoral head. J Arthroplasty, 2020; 35(2):325–330; doi: 10.1016/j.arth.2019.09.001
15.
McGrathMS, MarkerDR, SeylerTM, et al.Surface replacement is comparable to primary total hip arthroplasty. Clin Orthop Relat Res, 2009; 467(1):94–100; doi: 10.1007/s11999-008-0478-y
16.
Al-MousawiF, MalkiA, Al-AradiA, et al.Total hip replacement in sickle cell disease. Int Orthop, 2002; 26(3):157–161; doi: 10.1007/s00264-002-0337-5
17.
BeauléPE, SchmalzriedTP, CampbellP, et al.Duration of symptoms and outcome of hemiresurfacing for hip osteonecrosis. Clin Orthop Relat Res, 2001(385):104–117; doi: 10.1097/00003086-200104000-00018
18.
CalderPR, HynesMC, ScottG. Short-term results of hemi-resurfacing for osteonecrosis of the femoral head. Hip Int, 2004; 14(3):174–181; doi: 10.1177/112070000401400305
19.
ZhengY, ZhengZ, ZhangK, et al.Osteonecrosis in systemic lupus erythematosus: Systematic insight from the epidemiology, pathogenesis, diagnosis and management. Autoimmun Rev, 2022; 21(2):102992; doi: 10.1016/j.autrev.2021.102992
20.
HoogervorstP, CampbellJC, ScholzN, et al.Core decompression and bone marrow aspiration concentrate grafting for osteonecrosis of the femoral head. J Bone Joint Surg Am, 2022; 104(Suppl 2):54–60; doi: 10.2106/jbjs.20.00527
21.
WangX, HuL, WeiB, et al.Regenerative therapies for femoral head necrosis in the past two decades: A systematic review and network meta-analysis. Stem Cell Res Ther, 2024; 15(1):21; doi: 10.1186/s13287-024-03635-1
LouP, ZhouG, WeiB, et al.Bone grafting for femoral head necrosis in the past decade: A systematic review and network meta-analysis. Int J Surg, 2023; 109(3):412–418; doi: 10.1097/js9.0000000000000231
24.
HinesJT, JoWL, CuiQ, et al.Osteonecrosis of the femoral head: An updated review of ARCO on pathogenesis, staging and treatment. J Korean Med Sci, 2021; 36(24):e177; doi: 10.3346/jkms.2021.36.e177
25.
TrachtenbergJE, VoTN, MikosAG. Pre-clinical characterization of tissue engineering constructs for bone and cartilage regeneration. Ann Biomed Eng, 2015; 43(3):681–696; doi: 10.1007/s10439-014-1151-0
26.
DimitriouR, JonesE, McGonagleD, et al.Bone regeneration: Current concepts and future directions. BMC Med, 2011; 9:66; doi: 10.1186/1741-7015-9-66
27.
AriaM, CuccurulloC. bibliometrix: An R-tool for comprehensive science mapping analysis. J Informetr, 2017; 11(4):959–975.
28.
van EckNJ, WaltmanL. Visualizing Bibliometric Networks. In: Measuring Scholarly Impact: Methods and Practice. (DingY, RousseauR, WolframD. eds) Springer International Publishing: Cham; 2014; pp. 285–320.
29.
Perianes-RodriguezA, WaltmanL, Van EckNJ. Constructing bibliometric networks: A comparison between full and fractional counting. J Informetr, 2016; 10(4):1178–1195.
30.
HouJ, YangX, ChenC, et al.Emerging trends and new developments in information science: A document co-citation analysis (2009-2016). Scientometrics: An International Journal for All Quantitative Aspects of the Science of Science Policy, 2018; 115(2):869–892.
31.
SabeM, PillingerT, KaiserS, et al.Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends. Neurosci Biobehav Rev, 2022; 136:104608.
32.
WeiF, ZhangG. Exploring the intellectual structure and evolution of 24 top business journals: A scientometric analysis. EL, 2020; 38(3):493–511.
33.
ZhaoY, LiS, FengM, et al.Effects of Puerarin-Loaded tetrahedral framework nucleic acids on osteonecrosis of the femoral head. Small, 2023; 19(41):e2302326; doi: 10.1002/smll.202302326
34.
ZhangF, PengW, WangT, et al.Lnc Tmem235 promotes repair of early steroid-induced osteonecrosis of the femoral head by inhibiting hypoxia-induced apoptosis of BMSCs. Exp Mol Med, 2022; 54(11):1991–2006; doi: 10.1038/s12276-022-00875-0
35.
ZhangF, WeiL, WangL, et al.FAR591 promotes the pathogenesis and progression of SONFH by regulating Fos expression to mediate the apoptosis of bone microvascular endothelial cells. Bone Res, 2023; 11(1):27; doi: 10.1038/s41413-023-00259-8
36.
ZhaoDW, YuM, HuK, et al.Prevalence of nontraumatic osteonecrosis of the femoral head and its associated risk factors in the Chinese population: Results from a nationally representative survey. Chin Med J (Engl), 2015; 128(21):2843–2850; doi: 10.4103/0366-6999.168017
37.
ZhuW, XuR, DuJ, et al.Zoledronic acid promotes TLR-4-mediated M1 macrophage polarization in bisphosphonate-related osteonecrosis of the jaw. Faseb J, 2019; 33(4):5208–5219; doi: 10.1096/fj.201801791RR
38.
WeberM, HommA, MüllerS, et al.Zoledronate causes a systemic shift of macrophage polarization towards M1 in vivo. Int J Mol Sci, 2021; 22(3):1323; doi: 10.3390/ijms22031323
39.
AdapalaNS, YamaguchiR, PhippsM, et al.Necrotic bone stimulates proinflammatory responses in macrophages through the activation of toll-like receptor 4. Am J Pathol, 2016; 186(11):2987–2999; doi: 10.1016/j.ajpath.2016.06.024
40.
ChengY, ChenH, DuanP, et al.Early depletion of M1 macrophages retards the progression of glucocorticoid-associated osteonecrosis of the femoral head. Int Immunopharmacol, 2023; 122:110639; doi: 10.1016/j.intimp.2023.110639
41.
ZhaoD, CuiW, LiuM, et al.Tetrahedral framework nucleic acid promotes the treatment of bisphosphonate-related osteonecrosis of the jaws by promoting angiogenesis and M2 polarization. ACS Appl Mater Interfaces, 2020; 12(40):44508–44522; doi: 10.1021/acsami.0c13839
42.
JiangC, ZhouZ, LinY, et al.Astragaloside IV ameliorates steroid-induced osteonecrosis of the femoral head by repolarizing the phenotype of pro-inflammatory macrophages. Int Immunopharmacol, 2021; 93:107345; doi: 10.1016/j.intimp.2020.107345
43.
LongJ, YaoZ, ZhangW, et al.Regulation of osteoimmune microenvironment and osteogenesis by 3D-Printed PLAG/black phosphorus scaffolds for bone regeneration. Adv Sci (Weinh), 2023; 10(28):e2302539; doi: 10.1002/advs.202302539
44.
LuoY, YangZ, ZhaoX, et al.Immune regulation enhances osteogenesis and angiogenesis using an injectable thiolated hyaluronic acid hydrogel with lithium-doped nano-hydroxyapatite (Li-nHA) delivery for osteonecrosis. Mater Today Bio, 2024; 25:100976; doi: 10.1016/j.mtbio.2024.100976
45.
FanX, XuX, WuX, et al.The protective effect of DNA aptamer on osteonecrosis of the femoral head by alleviating TNF-α-mediated necroptosis via RIP1/RIP3/MLKL pathway. J Orthop Translat, 2022; 36:44–51; doi: 10.1016/j.jot.2022.07.001
46.
HouR, LeiJ, XueD, et al.The association of an elevated Th/Ts ratio and lupus anticoagulant with symptomatic osteonecrosis in systemic lupus erythematosus patients. Front Immunol, 2024; 15:1288234; doi: 10.3389/fimmu.2024.1288234
47.
LiuC, WangC, LiuY, et al.Selenium nanoparticles/carboxymethyl chitosan/alginate antioxidant hydrogel for treating steroid-induced osteonecrosis of the femoral head. Int J Pharm, 2024; 653:123929; doi: 10.1016/j.ijpharm.2024.123929
48.
XuH, FangL, ZengQ, et al.Glycyrrhizic acid alters the hyperoxidative stress-induced differentiation commitment of MSCs by activating the Wnt/β-catenin pathway to prevent SONFH. Food Funct, 2023; 14(2):946–960; doi: 10.1039/d2fo02337g
49.
LevineDC, KuoHY, HongHK, et al.NADH inhibition of SIRT1 links energy state to transcription during time-restricted feeding. Nat Metab, 2021; 3(12):1621–1632; doi: 10.1038/s42255-021-00498-1
50.
UngurianuA, ZanfirescuA, MarginăD. Sirtuins, resveratrol and the intertwining cellular pathways connecting them. Ageing Res Rev, 2023; 88:101936; doi: 10.1016/j.arr.2023.101936
51.
ChenL, WangBZ, XieJ, et al.Therapeutic effect of SIRT3 on glucocorticoid-induced osteonecrosis of the femoral head via intracellular oxidative suppression. Free Radic Biol Med, 2021; 176:228–240; doi: 10.1016/j.freeradbiomed.2021.07.016
52.
CuiY, ZhangW, YangP, et al.Menaquinone-4 prevents medication-related osteonecrosis of the jaw through the SIRT1 signaling-mediated inhibition of cellular metabolic stresses-induced osteoblast apoptosis. Free Radic Biol Med, 2023; 206:33–49; doi: 10.1016/j.freeradbiomed.2023.06.022
53.
YangN, SunH, XueY, et al.Inhibition of MAGL activates the Keap1/Nrf2 pathway to attenuate glucocorticoid-induced osteonecrosis of the femoral head. Clin Transl Med, 2021; 11(6):e447; doi: 10.1002/ctm2.447
54.
JiangH, LinC, CaiT, et al.Taxifolin-mediated Nrf2 activation ameliorates oxidative stress and apoptosis for the treatment of glucocorticoid-induced osteonecrosis of the femoral head. Phytother Res, 2024; 38(1):156–173; doi: 10.1002/ptr.8031
55.
GaoY, YouY, ZhangP, et al.Cortistatin prevents glucocorticoid-associated osteonecrosis of the femoral head via the GHSR1a/Akt pathway. Commun Biol, 2024; 7(1):132; doi: 10.1038/s42003-024-05795-5
56.
JiangH, WangW, MaoY, et al.Morroniside-mediated mitigation of stem cell and endothelial cell dysfunction for the therapy of glucocorticoid-induced osteonecrosis of the femoral head. Int Immunopharmacol, 2024; 127:111421; doi: 10.1016/j.intimp.2023.111421
57.
LinC, JiangH, LouC, et al.Asiatic acid prevents glucocorticoid-induced femoral head osteonecrosis via PI3K/AKT pathway. Int Immunopharmacol, 2024; 130:111758; doi: 10.1016/j.intimp.2024.111758
58.
PengB, ChenY, LeongKW. MicroRNA delivery for regenerative medicine. Adv Drug Deliv Rev, 2015; 88:108–122; doi: 10.1016/j.addr.2015.05.014
59.
YangL, LiY, GongR, et al.The Long Non-coding RNA-ORLNC1 regulates bone mass by directing mesenchymal stem cell fate. Mol Ther, 2019; 27(2):394–410; doi: 10.1016/j.ymthe.2018.11.019
60.
JinC, JiaL, TangZ, et al.Long non-coding RNA MIR22HG promotes osteogenic differentiation of bone marrow mesenchymal stem cells via PTEN/AKT pathway. Cell Death Dis, 2020; 11(7):601; doi: 10.1038/s41419-020-02813-2
61.
KimDK, BandaraG, ChoYE, et al.Mastocytosis-derived extracellular vesicles deliver miR-23a and miR-30a into pre-osteoblasts and prevent osteoblastogenesis and bone formation. Nat Commun, 2021; 12(1):2527; doi: 10.1038/s41467-021-22754-4
62.
YuL, SuiB, FanW, et al.Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1-targeting miRNA-92a-1-5p. J Extracell Vesicles, 2021; 10(3):e12056; doi: 10.1002/jev2.12056
63.
XuC, ZhangZ, LiuN, et al.Small extracellular vesicle-mediated miR-320e transmission promotes osteogenesis in OPLL by targeting TAK1. Nat Commun, 2022; 13(1):2467; doi: 10.1038/s41467-022-29029-6
64.
LiaoW, NingY, XuHJ, et al.BMSC-derived exosomes carrying microRNA-122-5p promote proliferation of osteoblasts in osteonecrosis of the femoral head. Clin Sci (Lond), 2019; 133(18):1955–1975; doi: 10.1042/cs20181064
65.
KuangMJ, ZhangKH, QiuJ, et al.Exosomal miR-365a-5p derived from HUC-MSCs regulates osteogenesis in GIONFH through the Hippo signaling pathway. Mol Ther Nucleic Acids, 2021; 23:565–576; doi: 10.1016/j.omtn.2020.12.006
66.
NanK, ZhangY, ZhangX, et al.Exosomes from miRNA-378-modified adipose-derived stem cells prevent glucocorticoid-induced osteonecrosis of the femoral head by enhancing angiogenesis and osteogenesis via targeting miR-378 negatively regulated suppressor of fused (Sufu). Stem Cell Res Ther, 2021; 12(1):331; doi: 10.1186/s13287-021-02390-x
67.
KongL, ZuoR, WangM, et al.Silencing MicroRNA-137-3p, which Targets RUNX2 and CXCL12 prevents steroid-induced osteonecrosis of the femoral head by facilitating osteogenesis and angiogenesis. Int J Biol Sci, 2020; 16(4):655–670; doi: 10.7150/ijbs.38713
68.
XuY, JiangY, WangY, et al.LINC00473-modified bone marrow mesenchymal stem cells incorporated thermosensitive PLGA hydrogel transplantation for steroid-induced osteonecrosis of femoral head: A detailed mechanistic study and validity evaluation. Bioeng Transl Med, 2022; 7(2):e10275; doi: 10.1002/btm2.10275
69.
ZuoR, KongL, WangM, et al.Exosomes derived from human CD34(+) stem cells transfected with miR-26a prevent glucocorticoid-induced osteonecrosis of the femoral head by promoting angiogenesis and osteogenesis. Stem Cell Res Ther, 2019; 10(1):321; doi: 10.1186/s13287-019-1426-3
70.
ChenXJ, ShenYS, HeMC, et al.Polydatin promotes the osteogenic differentiation of human bone mesenchymal stem cells by activating the BMP2-Wnt/β-catenin signaling pathway. Biomed Pharmacother, 2019; 112:108746; doi: 10.1016/j.biopha.2019.108746
71.
YuH, LiuP, ZhuD, et al.Chrysophanic acid shifts the differentiation tendency of BMSCs to prevent alcohol-induced osteonecrosis of the femoral head. Cell Prolif, 2020; 53(8):e12871; doi: 10.1111/cpr.12871
72.
DuanL, ZuoJ, ZhangF, et al.Magnetic Targeting of HU-MSCs in the treatment of glucocorticoid-associated osteonecrosis of the femoral head through Akt/Bcl2/Bad/Caspase-3 pathway. Int J Nanomedicine, 2020; 15:3605–3620; doi: 10.2147/ijn.S244453
73.
XuH, WangC, LiuC, et al.Cotransplantation of mesenchymal stem cells and endothelial progenitor cells for treating steroid-induced osteonecrosis of the femoral head. Stem Cells Transl Med, 2021; 10(5):781–796; doi: 10.1002/sctm.20-0346
74.
KongN, YangH, TianR, et al.An injectable self-adaptive polymer as a drug carrier for the treatment of nontraumatic early-stage osteonecrosis of the femoral head. Bone Res, 2022; 10(1):28; doi: 10.1038/s41413-022-00196-y
75.
ZhuT, JiangM, ZhangM, et al.Biofunctionalized composite scaffold to potentiate osteoconduction, angiogenesis, and favorable metabolic microenvironment for osteonecrosis therapy. Bioact Mater, 2022; 9:446–460; doi: 10.1016/j.bioactmat.2021.08.005
76.
WangCJ, HuangCC, YipHK, et al.Dosage effects of extracorporeal shockwave therapy in early hip necrosis. Int J Surg, 2016; 35:179–186; doi: 10.1016/j.ijsu.2016.09.013
77.
DaltroGC, FortunaV, de SouzaES, et al.Efficacy of autologous stem cell-based therapy for osteonecrosis of the femoral head in sickle cell disease: A five-year follow-up study. Stem Cell Res Ther, 2015; 6(1):110; doi: 10.1186/s13287-015-0105-2
78.
JungJ, YooHY, KimGT, et al.Short-Term Teriparatide and Recombinant Human Bone Morphogenetic Protein-2 for Regenerative Approach to Medication-Related Osteonecrosis of the Jaw: A Preliminary Study. J Bone Miner Res, 2017; 32(12):2445–2452; doi: 10.1002/jbmr.3237
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
